OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Ovarian, Fallopian Tube & Primary Peritoneal Cancer Overview

Ovarian, Fallopian Tube & Primary Peritoneal Cancer — All 22 Unranked Reference Options

Provenance SHA-256: 26ecbff635059c76 · Protocol drug dosing hard-excluded in Patient Edition.

Option / Regimen FamilyCategory & StatusCurated Source IDs
Mirvetuximab soravtansine
Selected FRα/test/prior-regimen conditions are source-linked.
selected_indicated_therapy
FDA indication exists; only selected conditions checked.
mirv, mirv-label
Pembrolizumab + paclitaxel ± bevacizumab
Selected PD-L1/test/prior-regimen conditions are source-linked.
selected_indicated_therapy
FDA combination indication exists; optional bevacizumab requires separate review.
pembro, pembro-label, paclitaxel-label, bev-label
Relacorilant + nab-paclitaxel
Selected prior-regimen and prior-bevacizumab conditions are source-linked.
selected_indicated_therapy
FDA combination indication exists; full safety assessment remains required.
rela, rela-label, nab-paclitaxel-label
Paclitaxel (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapy
Ovarian indication exists; the contemplated schedule requires review.
nci, paclitaxel-label
Pegylated liposomal doxorubicin (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapy
Ovarian post-platinum indication exists; complete applicability remains unassessed.
nci, pld-label
Topotecan (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapy
HYCAMTIN ovarian indication exists; verify current product and schedule labeling.
nci, topotecan-label
Gemcitabine (single agent; off-label here)
NCI discusses single-agent use in platinum-resistant recurrence.
conventional_therapy
Off-label in this setting as monotherapy; the labeled ovarian combination concerns platinum-sensitive relapse.
nci, gemcitabine-label
Bevacizumab + paclitaxel
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapy
FDA combination indication exists; selected conditions and safety inventory only.
bev-label, nci, paclitaxel-label
Bevacizumab + pegylated liposomal doxorubicin
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapy
FDA combination indication exists; selected conditions and safety inventory only.
bev-label, nci, pld-label
Bevacizumab + topotecan
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapy
FDA combination indication exists; selected conditions and safety inventory only.
bev-label, nci, topotecan-label
Pembrolizumab alone (MSI-H or dMMR solid tumours)
Gated only on what KEYTRUDA §1.8 states and the record holds: MSI-H or dMMR result, an FDA-authorized test, and progression after earlier treatment. Route: a subcutaneous form, KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa), is approved for the same MSI-H or dMMR solid-tumour use; it has its own dose and route and is not interchangeable with intravenous pembrolizumab.
selected_indicated_therapy
FDA label indication (KEYTRUDA §1.8). The §1.8 paragraph carries no accelerated-approval statement in SPL version 229.
pembro-msi-label
Dostarlimab alone (dMMR solid tumours)
Current JEMPERLI §1.3/§2.1 plus the therapy-specific FDA companion-diagnostic intended use: reviewed VENTANA dMMR or MI Cancer Seek MSI-H. An unverified or different assay calls for report/intended-use review; it is not automatically a clinical exclusion or an instruction to repeat IHC.
selected_indicated_therapy
FDA accelerated approval, JEMPERLI §1.3; no satisfactory alternative remains a clinician judgement. §2.1 selection and the named FDA PMA intended uses are checked separately from historical GARNET evidence.
jemperli-label-v15-selection, ventana-p210001-jemperli, mi-cancer-seek-p240010-jemperli, dostarlimab-label
Trastuzumab deruxtecan alone (HER2 IHC 3+ solid tumours)
Gated only on what ENHERTU §1.6 states and the record holds: HER2 IHC 3+ and earlier systemic treatment. The label names no scoring criteria for this use and says no FDA-authorized test for it is available, so neither is a gate.
selected_indicated_therapy
FDA accelerated approval (ENHERTU §1.6), based on objective response rate and duration of response; continued approval may depend on a confirmatory trial.
tdxd-label
Clinical-trial review
Trial consideration is part of review in this setting.
care_pathway
Not a named-trial match, enrollment determination or trial availability claim.
nci
Supportive and palliative care review
Concurrent symptom relief and goals-of-care review.
care_pathway
A care review pathway, not a medication or hospice-eligibility decision.
palliative
Carboplatin + paclitaxel (platinum-sensitive recurrence; ICON4 / GOG-0213)
Improved 2-year survival (57% vs 50%) and median OS (29 vs 24 months) vs conventional platinum therapy in ICON4.
conventional_therapy
FDA platinum/taxane palliative recurrent ovarian indications; randomized survival advantage over non-taxane platinum in ICON4.
carboplatin, paclitaxel, pm_12826431, pdq_ovarian
Carboplatin + paclitaxel + bevacizumab -> bevacizumab maintenance (GOG-0213)
Improved median PFS (13.8 vs 10.4 months, HR 0.61) and ORR (78% vs 56%) over carboplatin + paclitaxel in GOG-0213.
selected_indicated_therapy
FDA-approved in combination with carboplatin and paclitaxel followed by single-agent Avastin for platinum-sensitive recurrent ovarian cancer (AVASTIN §1.9).
avastin, carboplatin, paclitaxel, pm_28438473, pdq_ovarian
Carboplatin + gemcitabine (platinum-sensitive recurrence >=6m; Study 1)
Improved median PFS (8.6 vs 5.8 months, HR 0.72) and ORR (47.2% vs 30.9%) over single-agent carboplatin in Study 1.
selected_indicated_therapy
FDA-approved gemcitabine in combination with carboplatin for advanced ovarian cancer relapsed at least 6 months after completion of platinum-based therapy (gemcitabine §1.1).
gemcitabine, carboplatin, pdq_ovarian
Carboplatin + gemcitabine + bevacizumab -> bevacizumab maintenance (OCEANS / AVF4095g)
Improved median PFS (12.4 vs 8.4 months, HR 0.46-0.484) and ORR (78.5% vs 57.4%) in OCEANS; no OS improvement.
selected_indicated_therapy
FDA-approved in combination with carboplatin and gemcitabine followed by single-agent Avastin for platinum-sensitive recurrent ovarian cancer (AVASTIN §1.9; OCEANS enrolled no prior recurrent chemo and no prior bevacizumab).
avastin, gemcitabine, carboplatin, pm_22529265, pdq_ovarian
Carboplatin + pegylated liposomal doxorubicin (CALYPSO)
Longer median PFS vs carboplatin + paclitaxel (11.3 vs 9.4 months, HR 0.823) with lower alopecia/neuropathy and similar OS in CALYPSO (NCI PDQ).
conventional_therapy
Prospective phase 3 noninferiority/superiority PFS trial CALYPSO summarized in NCI PDQ ovarian treatment summary; neuropathy-sparing platinum doublet.
doxil, carboplatin, pdq_ovarian
BRCA-mutated PARP inhibitor maintenance after response to platinum (SOLO-2 / NOVA / ARIEL3)
Substantial PFS prolongation in BRCA-mutated platinum-sensitive recurrent maintenance (SOLO-2 19.1 vs 5.5m; NOVA gBRCAmut 21.0 vs 5.5m; ARIEL3 tBRCA 16.6 vs 5.4m).
selected_indicated_therapy
FDA-approved maintenance for recurrent ovarian cancer in CR/PR to platinum: olaparib (LYNPARZA §1.2, germline or somatic BRCA), niraparib (ZEJULA §1.2, deleterious/suspected deleterious germline BRCA ONLY), rucaparib (RUBRACA §1.2, deleterious BRCA germline or somatic).
lynparza, zejula, rubraca
Secondary cytoreductive surgery evaluation before platinum therapy (DESKTOP III)
Longer median OS with cytoreductive surgery + platinum chemotherapy vs chemotherapy alone (53.7 vs 46.0 months, HR 0.75) when selected by positive AGO score (75.5% macroscopic complete resection).
care_pathway
Prospective randomized phase 3 trial DESKTOP III (NCT01166737; PMID 34874631) in first platinum-sensitive relapse (>=6 months) with positive AGO score (ECOG 0, complete resection at 1L surgery, ascites <500 mL).
pm_34874631, pdq_ovarian